FDA Drug Approvals and Regulatory Updates The table below is a review of notable updates that occurred in June 2026 for investigational products in development (not an inclusive list). Click on the ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into ...

Forte Biosciences offers upside as FB102 demonstrates efficacy in celiac disease and vitiligo, suggesting platform potential ...

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...

Celldetective is an open-source software integrating segmentation, tracking, and event detection to perform high-throughput end-to-end study of dynamic cell interactions, without requiring coding ...

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most ...

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein C-III-directed antisense oligonucleotide ...

NANJING, China, July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been ...